Novartis' canakinumab cuts risk for heart attack survivors

06:36 EDT 22 Jun 2017 | pharmaphorum

A drug currently marketed as an anti-inflammatory treatment could be Novartis' next cardiovascular blockbuster, after it showed success in cutting risk for heart attack survivors. Canakinumab is the active ingredient in Novartis’ Ilaris, used...

Original Article: Novartis' canakinumab cuts risk for heart attack survivors


More From BioPortfolio on "Novartis' canakinumab cuts risk for heart attack survivors"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...